Announcements Trials
Browse Landscape Eligibility

Clinical Trials

1 trials
RecentStart dateEnrollment
SCCHN × Clear all

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 11735Neoplasms 9361Carcinoma, Non-Small-Cell Lung 6100Prostatic Neoplasms 5640Colorectal Neoplasms 5275Lung Neoplasms 4518Multiple Myeloma 3186Pancreatic Neoplasms 3174Neoplasm Metastasis 3120Leukemia, Myeloid, Acute 3104Carcinoma, Hepatocellular 2907Ovarian Neoplasms 2832Melanoma 2805Stomach Neoplasms 2722Lymphoma 2681Head and Neck Neoplasms 2313Recurrence 2268Precursor Cell Lymphoblastic Leukemia-Lymphoma 2207Leukemia 2131Brain Neoplasms 2099Colonic Neoplasms 2065Lymphoma, Non-Hodgkin 2019Rectal Neoplasms 1955Uterine Cervical Neoplasms 1910Glioblastoma 1813Leukemia, Lymphocytic, Chronic, B-Cell 1776Carcinoma, Renal Cell 1700Squamous Cell Carcinoma of Head and Neck 1651Lymphoma, Follicular 1631Esophageal Neoplasms 1603

Interventions

pembrolizumab 1demplatin pegraglumer 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements
NCT03771820 2021-03-17

Combination Therapy With NC-6004 and Pembrolizumab in Head and Neck Cancer Subjects Who Have Failed Platinum Regimen

NanoCarrier Co., Ltd.

Phase 2 Unknown
136 enrolled

SCCHN

Data powered by HemOnc (CC BY 4.0) Colophon âš¡